| 초록 |
Triple-negative breast cancer (TNBC) has an aggressive phenotype with lack expression of estrogen receptor, progesterone receptor, and HER2. Its treatment options are currently limited to the conventional chemotherapy. In order to overcome its overall therapeutic outcomes, we designed a targeted therapy platform using Trop2 that was identified cell surface glycoprotein overexpressed in 80% of TNBC patients. anti-Trop2 antibody was conjugated to polymeric nanoparticles (TNPs) based on carboxymethyl dextran derivatives with bioreducible disulfide bonds. Anti cancer drug, doxorubicin (DOX) was encapsulated in TNPs by physical method. DOX-TNPs were selectively taken up by Trop2-expressing TNBC cells. The release rate of encapsulated model from DOX-TNPs increased rapidly at the intracellular reductive environment due to the cleavage of disulfide bonds. Overall, TNPs showed a potential as a TNBC-targeting drug carrier. |
